Disease spectrum and treatment patterns in a local male infertility clinic

published_or_final_versio

Disease spectrum and treatment patterns in a local male infertility clinic

published_or_final_versio

Initial results of selective renal parenchymal clamping with an adjustable kidney clamp in nephron-sparing surgery: an easy way to minimise renal ischaemia

published_or_final_versio

Impact of skeletal-related events on survival in patients with metastatic prostate cancer prescribed androgen deprivation therapy

published_or_final_versio

Use of the International Prostate Symptom Score (IPSS) in Chinese male patients with benign prostatic hyperplasia

Purpose: To test the psychometric properties of the International Prostate Symptom Score (Hong Kong Chinese version 2) (IPSS) in Chinese male patients with benign prostatic hyperplasia (BPH) under secondary care. Methods: A prospective longitudinal study was done by interviewing subjects at baseline, at 2 week after baseline for assessing test–retest reliability and at 26 week after baseline for assessing responsiveness. All subjects were interviewed to complete a structured questionnaire including IPSS, Short Form-12 Health Survey version 2 (SF-12v2) and Depression Anxiety Stress Scale (DASS). Results: The IPSS HRQOL score had weak correlations with SF-12v2 summary and DASS domain scores. For reliability analysis, Cronbach’s alpha coefficient was 0.90 for the seven symptom-related items. The intraclass correlation coefficients of the IPSS total symptom score and HRQOL score were 0.90 and 0.86, respectively. For sensitivity, statistically significant differences were detected between the subjects with BPH and those without for IPSS total symptom score (effect size=0.68) but not the IPSS HRQOL score. The areas under ROC curves for the IPSS total symptom and HRQOL scores were 0.67 and 0.60, respectively. Conclusions: The IPSS was valid, reliable instrument in Chinese patients with BPH. The IPSS total symptom score, but not the HRQOL score, is sensitive in differentiating subgroups

Avoiding infection after prostate biopsy

Invited LectureOrganized by The University of Hong Kong and American College of Surgeon

Challenges facing organ donation/transplantation

Invited Lectur

Mini-PCNL in a toddler

Abstract and video presentationTheme: MIS in Urology: Past, Present and Futur

How have we treated pathological T1 (pT1) prostate cancer (CaP) in recent 10 years?

Oral PresentationObjective: To review the treatment modality and outcome of patients with pT1 CaP. Patients & Methods: Data of transurethral resection of prostate (TURP) performed from April 2000 to December 2009 were reviewed. Pathological results of resected specimen were reviewed on electronic patient record (ePR) system and data of patients with pT1 CaP were retrieved. Kaplan-Meier model was used to compare survival. Results: During the period, 178 patients were diagnosed pT1 prostate cancer with median follow-up time of 57.5 months. Median age at TURP was 77 years old. 97 (54.5%) patients had pT1a CaP and 65 (36.5%) had pT1b CaP; extent of tumour involvement was not reported in 16 (9%) specimens. 9 (5.1%) patients underwent curative treatment – radical prostatectomy (RP) (2.2%) or radical radiotherapy (RT) (3.4%); 48 (27.5%) received palliative treatment – bilateral simple orchidectomy (BSO) (13.2%), anti-androgen monotherapy (10.7%) and luteinizing hormone receptor hormone antagonist (LHRHa) injection (3.4%); 5 (2.8%) patients had active surveillance (AS) and 111 (62.4%) decided for watchful waiting (WW). Most patients died of CaP-unrelated causes. The overall and disease-specific 5-year survival were 33% and 100% for RP, 42% and 83% for RT, 10% and 48% for BSO, 12% and 100% for anti-androgen monotherapy, 67% and 100% for LHRHa, 100% and 100% for AS, and 45% and 92% for WW, respectively. Conclusions: Most patients with pT1 CaP died of CaP-unrelated causes. Treatment plan should be discussed with patients with balance of survival benefit, benefit in improving quality of life and complications of treatment